H
Harsh Agrawal
Researcher at University of California, San Francisco
Publications - 45
Citations - 2278
Harsh Agrawal is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Coronary artery disease & Heart failure. The author has an hindex of 14, co-authored 43 publications receiving 2064 citations. Previous affiliations of Harsh Agrawal include San Francisco VA Medical Center & Texas Tech University Health Sciences Center.
Papers
More filters
Journal ArticleDOI
2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
Jasvinder A. Singh,Daniel E. Furst,Aseem Bharat,Jeffrey R. Curtis,Arthur Kavanaugh,Joel M. Kremer,Larry W. Moreland,James O'Dell,Kevin L. Winthrop,Timothy Beukelman,S. Louis Bridges,W. Winn Chatham,Harold E. Paulus,Maria E. Suarez-Almazor,Claire Bombardier,Maxime Dougados,Dinesh Khanna,Charles M. King,Amye L. Leong,Eric L. Matteson,John T. Schousboe,Eileen Moynihan,Karen S. Kolba,Archana Jain,Elizabeth R. Volkmann,Harsh Agrawal,Sangmee Bae,Amy S. Mudano,Nivedita M. Patkar,Kenneth G. Saag +29 more
TL;DR: The 2012 ACR RA recommendations were developed by two expert panels: a non-voting working group and Core Expert Panel of clinicians and methodologists responsible for the selection of the relevant topic areas to be considered, the systematic literature review, and the evidence synthesis.
Journal ArticleDOI
Obesity and heart failure: epidemiology, pathophysiology, clinical manifestations, and management.
TL;DR: Substantial weight loss in severely obese persons is capable of reversing most obesity-related abnormalities of cardiac performance and morphology and improving the clinical manifestations of obesity cardiomyopathy.
Journal ArticleDOI
Dendritic cells and aging: consequences for autoimmunity
TL;DR: An overview of the effects of advancing age on DC functions and their implications in autoimmunity is provided.
Journal ArticleDOI
Infection and Lupus: Which Causes Which?
TL;DR: Current knowledge of the infectious risk SLE patients face as a result of their underlying disease including abnormal phagocytes and T cells as well as the increased risk of infection associated with immunosuppressive agents used to treat disease are summarized.
Journal ArticleDOI
Infliximab may be effective in the treatment of steroid-resistant eosinophilic fasciitis: report of three cases.
TL;DR: Infliximab may be beneficial in patients with steroid-resistant EF, and all patients noticed an improvement in their symptoms, joint contractures and skin thickening within 8 weeks of starting inflIXimab therapy.